Posts

Showing posts with the label Mucosal melanoma competitive landscape

Mucosal Melanoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Mucosal melanoma originates from melanocytes residing in various internal epithelial tissues of ectodermal origin. These tumors predominantly affect elderly white males. Typically, mucosal melanomas manifest as polypoid growths in shades of brown, tan, or bluish hue, with the supraglottis being a common site of occurrence. Patients typically present with hoarseness, hemoptysis, sore throat, neck pain, and a sensation of a foreign object. These mucosal melanomas can be classified into subtypes based on their tissue of origin. They can initiate in any mucosal epithelium, with the most frequent sites being the respiratory tract, nasal cavity, paranasal sinuses, oral cavity, gastrointestinal tract, transitional zone of the anal canal, genitourinary tract, vulva, and vagina. The preferred treatment for individuals diagnosed with mucosal melanoma in the sinonasal tract is often endoscopic endonasal surgery, contingent upon the tumor's precise location. In cases where surgery is not feas...

Mucosal Melanoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
  Mucosal melanoma arises from melanocytes that reside in a range of internal epithelial tissues of ectodermal origin. The oral cavity, nose and paranasal sinuses, genital tract, and anorectal region are the commonest primary sites for mucosal melanoma. Mucosal melanoma is a rare disease, accounting for only 0.03% of new cancer diagnoses. According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses, an estimated 93,760 cases of melanoma were diagnosed in the United States in 2020, ~1.6% of them are on the mucosal surfaces of the body. Thelansis’s “Mucosal Melanoma Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Mucosal ...

Mucosal melanoma – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Image
  Mucosal melanoma arises from melanocytes that reside in a range of internal epithelial tissues of ectodermal origin. The oral cavity, nose and paranasal sinuses, genital tract, and anorectal region are the commonest primary sites for mucosal melanoma.   Epidemiology-   Mucosal melanoma is a rare disease, accounting for only 0.03% of new cancer diagnoses, According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses, estimated 93,760 cases of melanoma were diagnosed in the United States in 2020, ~1.6% of them are on the mucosal surfaces of the body.   The competitive landscape of Mucosal melanoma includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary. KOLs insights of Mucosal melanoma across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in th...